The prevalence of diabetes in many South Asian countries is above 10%, but type 1 diabetes (T1D) is not fully characterized due to a lack of widespread access to islet autoantibody (IA) testing. Determining the prevalence of IA positivity in new and recent onset cases of childhood diabetes in these countries will allow for improved classification of diabetes and may impact treatment. We measured IA directed against glutamic acid decarboxylase 65 (GADA), insulinoma antigen-2 (IA-2A), insulin (IAA) and zinc transporter 8 (ZnT8A) using fluid-phase radiobinding assays from dried blood spot eluents in children with diabetes from the Republic of Maldives (n=64), Bangladesh (n=103) and Pakistan (n=54). We compared the results to youth from our large diabetes Center in Colorado (n=132). South Asian children with clinically diagnosed T1D have a lower rate of positivity for each IA when compared to youth with T1D from Colorado (p<0.0001) (Figure). The majority of youth with T1D in each country were diagnosed at a young age, not overweight, and required insulin treatment. Interestingly, 52% of Bangladeshi youth are antibody negative (p<0.0001 compared to Colorado), yet 92% require insulin treatment, thus highlighting the need to investigate other forms of diabetes such as monogenic causes. Studying the phenotype of diabetes in youth across the globe provides an opportunity to dissect the heterogeneity within childhood onset diabetes.View largeDownload slideView largeDownload slide DisclosureK. Simmons: Other Relationship; Self; Provention Bio, Inc. E. M. Youngkin: None. A. Condie: None. A. Alkanani: None. K. Mcdaniel: None. L. Yu: None. G. D. Ogle: None. A. W. Michels: Stock/Shareholder; Self; IM Therapeutics.FundingNational Institutes of Health (K12DK094712-08)